Skaraborg Hospital-Vaestra Goetalandsregionen

Research site

Sweden Mellbygatan 11-15, 531 51 Lidkoping, Sweden

1 trial recruiting
Arteriosclerosis · Dyslipidaemia · Heart failure with preserved ejection fraction
Adult patients

About Specializations

Skaraborg Hospital-Vaestra Goetalandsregionen in Lidkoping, Sweden specialises in clinical trials of conditions such as Arteriosclerosis, Dyslipidaemia, Heart failure with preserved ejection fraction, Cholangitis sclerosing, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Mellbygatan 11-15531 51 LidkopingSweden

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 4

More sites in Lidkoping Sweden

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

4 clinical trials

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Sweden

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Sweden

Participants:18–64 years · 65+ years
Substances:Evolocumab
Sponsor:Amgen Inc.

Contact Research Centre

Heart failure with preserved ejection fraction

Not recruiting

Study of spironolactone and eplerenone in patients with heart failure with preserved ejection fraction (HFpEF)

Registered drugNo placebo

Study of spironolactone and eplerenone in patients with heart failure with preserved ejection fraction (HFpEF)

Registered drugNo placebo

Sweden

Participants:18–64 years · 65+ years
Substances:Altizide
Sponsor:Region Uppsala

Contact Research Centre

Cholangitis sclerosing

Not recruiting

Study on Simvastatin for Treating Primary Sclerosing Cholangitis in Patients

Registered drug

Study on Simvastatin for Treating Primary Sclerosing Cholangitis in Patients

Registered drug

Sweden

Participants:18–64 years · 65+ years
Substances:Simvastatin
Sponsor:Karolinska University Hospital

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites